Reagent for enabling bone mesenchymal stem cells (BMSCs) to target at myocardial infarction lesions and preparation method

Abstract

The invention provides a reagent for enabling bone mesenchymal stem cells (BMSCs) to target at myocardial infarction lesions. A culture medium for enabling the BMSCs to target at the myocardial infarction lesions is composed of a solute and a solvent, wherein the solute comprises 100% plasma, 400-700 U / mL of low-molecular-weight heparin sodium, 40-70 mmol / L of a dipotassium phosphate solution, 0.4-10 [mu]mol / L of adenosine, 0.5-10 mg / mL of ginsenoside Rb1, 4.5-5.5 g / L of glucose, 0.15-0.25 g / L of sodium carbonate, 0.590-0.710 g / L of L-glutamine, 50-65 g / L of transferrin, 5-7 g / L of insulin and0.01-0.05 g / L of a basic fibroblast growth factor; and the solvent is a compound electrolyte injection, a glucose injection or normal saline. The BMSCs subjected to intravenous injection can target at the myocardial infarction lesions, and the problem that the quantity of cells left by intracoronary injection at present is small is solved.

Description

technical field [0001] The invention relates to a reagent and a preparation method for targeting bone marrow mesenchymal stem cells to myocardial infarction, and belongs to the technical field of stem cells. Background technique [0002] Bone marrow mesenchymal stem cells are another type of stem cells besides hematopoietic stem cells in the bone marrow. They are an important part of the hematopoietic microenvironment of the bone marrow and can support and regulate hematopoiesis both in vivo and in vitro. Because it is easier to adhere to the wall and form fibrous clones, it is also called fibroblast colony forming unit. Under certain induction conditions, BMSCs have the ability to differentiate into mesoderm cells such as osteoblasts, adipocytes, skeletal muscle, chondrocyte smooth muscle, tenocytes, and hematopoietic support matrix; at the same time, they can differentiate into ectodermal astrocytes, Neuronal, vascular endothelial and cardiomyocyte differentiation. The p...

AI Technical Summary

Problems solved by technology

Treatment of acute myocardial infarction with intracoronary injection of stem cells has clinically relevant effects on restoration of cardiac function and heart deformation. Patients treated with cells did not have an increased need for targeted revascularization. The study found the treatment to be safe, although at first glance , intracoronary injection is one way of cell application, but radiolabeled bone marrow cells showed that: compared with intramuscular injection, intracoronary injection left a smaller amount of cells, but intramuscular injection can only be localized. Now there is an urgent need for a reagent and preparation method for targeting bone marrow mesenchymal stem cells to myocardial infarction to solve the above-mentioned problems